Aarti Drugs Limited (NSE: AARTIDRUGS, BSE: 524348), the Mumbai-headquartered pharmaceutical manufacturer, reported a steady financial performance in the first quarter of FY26, underpinned by stronger demand for active pharmaceutical ingredients (APIs) and a continued shift toward high-value formulations and specialty chemicals. Consolidated revenue rose 6% year-on-year to ₹590.8 crore for the quarter ended June 30, 2025, while profit after tax surged 62% year-on-year to ₹54 crore. The company achieved a 310-basis-point improvement in its profit after tax margin, reaching 9.1%, driven by better product mix and cost optimization efforts.
On a sequential basis, revenue declined 13% compared to the March 2025 quarter, and EBITDA fell 22% to ₹74.4 crore, reflecting seasonal weakness in API volumes and cost pressures from raw materials. However, analysts remain moderately positive on the long-term outlook, citing the company’s ongoing investments in backward integration, greenfield manufacturing capacity, and regulatory market approvals as potential catalysts for margin expansion.
The quarter’s gross profit grew 11% year-on-year to ₹217.4 crore, with gross margins improving 130 basis points to 36.8%. EBITDA margins also rose 70 basis points to 12.6%, despite the quarter-on-quarter dip from 14% in the previous period. Institutional investors indicated that the results reflected early signs of operational recovery, with a stronger product mix supporting profitability even as volume growth remained moderate.
How did Aarti Drugs’ segmental performance reflect the shift towards higher-margin formulations and specialty chemicals in Q1 FY26?
APIs remained the largest revenue contributor, generating ₹458.2 crore in Q1 FY26, up 4% year-on-year, but sequentially declining 17% due to seasonal demand patterns. Within the API business, the anti-biotic therapeutic category accounted for approximately 41% of sales, followed by anti-protozoal APIs at 19%, anti-diabetic APIs at 15%, anti-inflammatory APIs at 12%, and antifungal APIs at 10%. The remaining 4% was contributed by other therapeutic areas.
The formulations business delivered a robust 14% year-on-year growth, reaching ₹80.3 crore, with exports forming 57% of the segment’s revenue. Specialty chemicals posted a sharp 24% year-on-year growth to ₹33.1 crore, supported by higher demand for intermediates such as benzene sulphonyl chloride and methyl nicotinate. Intermediaries and other segments also grew 22% to ₹18.9 crore.
Standalone revenue reached ₹521.3 crore, with 65% derived from the domestic market and 35% from exports. While domestic revenue remained flat, export revenue increased 18% year-on-year, reflecting growing traction in regulated markets. Analysts noted that the company’s emphasis on regulated export markets, bolstered by recent United States Food and Drug Administration (USFDA) approvals, is gradually shifting its revenue mix toward higher-margin products.
Can backward integration and greenfield capacity expansions improve cost efficiency and secure API supply chains?
Aarti Drugs incurred approximately ₹48.5 crore in capital expenditure during the quarter, primarily allocated toward capacity expansion, backward integration, and formulation-focused research and development. Full-year capex is projected to be in the range of ₹150–200 crore.
The company has started trial production at its new greenfield manufacturing facility in Sayakha, Gujarat. This facility has been designed to produce anti-diabetic products and their intermediates, primarily for internal consumption. Management expects this backward integration initiative to reduce raw material cost volatility, improve profit margins, and enhance supply chain resilience.
The greenfield salicylic acid plant at Tarapur is progressing as planned and is expected to start contributing to financials from Q3 FY26. Initial startup challenges, typical of projects using in-house developed technology, have reportedly been addressed. Aarti Drugs has laid out a calibrated ramp-up roadmap to scale production to over 800 tonnes per month in the coming quarters, with plans to expand installed capacity to 1,600 tonnes per month by the end of FY26. The Tarapur facility has also triggered several new regulated customer audits, and additional production blocks are planned to further expand capacity.
Institutional sentiment remains cautiously optimistic about these initiatives. Analysts believe that successful ramp-up of Sayakha and Tarapur could deliver structural margin improvement and reduce reliance on external suppliers, although near-term gains may remain limited until the facilities achieve optimal utilization.
How do global trade policy changes, particularly U.S. tariffs on Chinese APIs, shape Aarti Drugs’ export growth outlook?
The recent announcement by the U.S. government to impose higher tariffs on pharmaceutical products and APIs imported from China is likely to accelerate a realignment of global supply chains. Indian API manufacturers with regulatory approvals are expected to benefit from this shift, as buyers diversify sourcing away from Chinese suppliers.
Aarti Drugs, with a recently USFDA-approved API facility and established manufacturing capabilities, is well-positioned to capitalize on this opportunity. The commissioning of new capacities at Sayakha and Tarapur enhances its ability to serve regulated export markets. Additionally, its formulation subsidiary has secured USFDA approval for its oncology facility and UK Medicines and Healthcare products Regulatory Agency (UKMHRA) approval for its oral solid dosage facility. The company is actively developing and registering new oncology dossiers, which are expected to contribute to regulated market growth from FY27 onwards.
Institutional investors view these developments as positive for Aarti Drugs’ long-term export outlook. Analysts expect a gradual shift in revenue mix toward regulated markets, which could support higher margins, although the company’s ability to secure long-term supply agreements will be critical in fully capturing the benefits of this global trade realignment.
What is the investor sentiment and future outlook for Aarti Drugs’ stock after Q1 FY26 results?
Investor sentiment toward Aarti Drugs remains moderately positive despite the quarter-on-quarter revenue and EBITDA declines. The strong year-on-year growth in profit after tax and expanding margins indicate that cost optimization and product mix changes are beginning to yield results. Analysts expect mid-single-digit revenue growth for FY26, with potential for stronger earnings growth in the second half of the fiscal year as new capacities come online.
The company’s strategic focus on backward integration, capacity expansion, and regulated market penetration positions it well for sustainable growth. However, execution risks related to greenfield project ramp-ups and potential raw material price volatility remain near-term challenges. Institutional investors are likely to monitor the company’s progress on scaling Sayakha and Tarapur facilities closely, as well as its ability to capitalize on opportunities arising from the U.S. tariff shifts.
If successfully executed, these initiatives could help Aarti Drugs transition into a higher-margin, export-driven pharmaceutical manufacturer with stronger visibility in regulated markets. By leveraging backward integration to stabilize input costs and expanding greenfield capacities to secure long-term supply contracts, the company has the potential to improve its earnings quality and reduce dependence on cyclical domestic demand. Its strategic positioning to benefit from the global realignment of API supply chains, coupled with oncology-focused dossier development for highly regulated markets, may also provide a significant competitive edge over smaller domestic peers. For investors, this combination of operational restructuring, export market penetration, and structural margin improvement makes Aarti Drugs an attractive medium-term play in the Indian pharmaceutical sector, particularly for those seeking exposure to companies with an emerging global footprint and a clear roadmap for sustainable earnings growth.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
